• Miki

This Pharmaceutical Company Sets Record Dividend Date At Rs. 150 Per Equity Share; Learn More

GlaxoSmithKline Dividend: The mid-cap pharmaceutical business GlaxoSmithKline has recommended a final dividend for FY 2022 and set the record date for the same. The company creates a variety of pharmaceutical, vaccine, and consumer healthcare goods in addition to manufacturing, selling, and distributing pharma products.

The Board has recommended a dividend of Rs. 90 (including a special dividend of Rs. 60) per equity share on the face value of Rs. 10 each for the year ended March 31, 2022, subject to approval by shareholders at the 97th Annual General Meeting to be held on Tuesday, July 26, 2022, according to a BSE exchange filing by the company. The Company has set Friday, July 8, 2022, as the Record Date for assessing the eligibility of members for the final dividend for the financial year ended March 31, 2022, by Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. If the members approve it, the dividend will be paid on or around Wednesday, July 27, 2022.

GlaxoSmithKline Shares: Dividend & Share Price History

The business has a solid dividend history, having routinely distributed dividends over the last five years. At the current share price of Rs 1514.90, the company's 300 percent dividend, or Rs 30 per share, is a 1.98 percent dividend yield for the fiscal year that concluded in FY21.

On a year-to-date (YTD) basis, the stock fell 1.91 percent in the prior year and 13.29 percent so far in 2022. The share price of GlaxoSmithKline Pharmaceuticals Ltd. has dropped 12.81% over the past six months and 2.34% over the past month. In the preceding five trading days, the stock's value has decreased by 2.47 percent. A 52-week high of Rs. 1,918.75 was reached by GlaxoSmithKline Pharmaceuticals Ltd. shares on December 13, 2021, and a 52-week low of Rs. 1,450.00 was reached on October 25, 2021. suggesting that the stock is currently trading 3.87 percent above its 52-week low and 21% below its 52-week high. Based on the most recent traded price, the stock is trading below the 5 days, 20-day, 50-day, 100-day, and 200-day moving averages.

For the March quarter, GlaxoSmithKline Pharmaceuticals reported a combined net loss from continuing operations of Rs 55 crore (Q4FY22). For Q4FY21, the pharmaceutical company declared a net profit of Rs 4 crore.

The pharmaceutical giant reported in a regulatory filing that operating revenue increased to Rs 810 crore for the fourth quarter from Rs 744 crore in the same quarter last year.

The company reported a consolidated net profit from continuing operations of Rs 381 crore for the fiscal year that ended on March 31, 2022, up from Rs 287 crore in FY21.

In its note dated May 17, ICICI Securities said: “The company’s positioning as a pure-play domestic formulator20-day and strong balance sheet with high brand equity are likely to act as key growth catalysts. Even while we anticipate that growth in acute therapies will continue in the upcoming quarters, it will be mild compared to last year's strong base. We think that the current price already accounts for the potential for immediate development. We upgrade the stock to HOLD (from Reduce) with a revised target price of Rs1,456/share (prior: Rs1,498/share)."

#glaxopharmashareprice #equityshare #pharmashare #recorddate

Read more Business, Entertainment, Social, Politics , Real Estate , Finance , Sports

0 views0 comments